Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01823510
Other study ID # GCO 13-0208
Secondary ID
Status Completed
Phase Phase 4
First received March 29, 2013
Last updated December 5, 2017
Start date July 2013
Est. completion date May 10, 2016

Study information

Verified date December 2017
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes. Both treatments will be given (separately) to all subjects as a one-time loading dose (i.e. higher than a normal daily dose), followed by daily dose for the next 5 to 7 days. Effectiveness of treatment will be measured with specialized blood tests before the loading dose, at two time-points after the loading dose, and once after the last daily dose.


Description:

The rising prevalence of diabetes mellitus and its associated cardiovascular complications present a major burden to healthcare providers worldwide. Cardiovascular mortality is much higher among subjects with Type 2 Diabetes Mellitus (T2DM). Increased platelet reactivity is considered a potential link between the two diseases. Thus, given the higher blood thrombogenicity of T2DM with CAD, the availability of more potent antiplatelet drugs should be associated with improvements in the prevention of cardiovascular events in the diabetic populations. Ticagrelor has been shown to possess a faster onset of action and more potency than clopidogrel. Furthermore, the PLATO has shown that these characteristics results in a significant reduction in Cardiovascular events and even death as compared with Clopidogrel.

We plan to compare the antithrombotic activity of ticagrelor versus clopidogrel in T2DM patients using a cross-over study design. Each participant will be randomly assigned to receive ticagrelor/clopidogrel + aspirin as a loading dose followed by 5-7 days of daily maintenance dosing. After a washout period of 1-2 weeks, each participant will receive the second treatment (clopidogrel/ticagrelor + aspirin) again as a loading dose followed by 5-7 days of daily dosing. Platelet function will be tested at pre-treatment baseline, two post-dose time-points on the day of loading dose, and one time-point after the last maintenance dose on day 5-7. Platelet testing will be carried out using the following methodologies:

1. Badimon Perfusion Chamber: an ex-vivo model of thrombosis that has been extensively utilized for evaluation of antithrombotic or prothrombotic effects under various pathological states. The model involves native blood perfusing over a thrombogenic substrate, triggering thrombus formation that can be measured by planimetry.

2. Platelet Aggregation - Multiplate Analyzer.

3. Platelet Aggregation - VerifyNow P2Y12 assay.

4. Vasodilator-Stimulated Phosphoprotein (VASP).


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 10, 2016
Est. primary completion date May 10, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Diagnosed with type-2 diabetes being treated with oral or parenteral hypoglycemic therapy or both.

- Have not had thienopyridine therapy for at least 30 days before the study.

- Are of legal age (at least 18 years of age but less than 75 years of age) and competent mental condition to provide written informed consent.

- For women of child-bearing potential only test negative for pregnancy at the time of enrollment.

Exclusion Criteria:

- Have a defined need for thienopyridine therapy.

- Subjects within =30 days of coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI).

- Known glycosylated hemoglobin (HbA1c) =10 mg/dL within last 3 months prior to study entry.

- Have received fibrinolytic therapy <48 hours prior to randomization.

- Have active internal bleeding or history of bleeding diathesis.

- Have clinical findings that are, in the judgment of the investigator, associated with an increased risk of bleeding.

- Have history of ischemic or hemorrhagic stroke, transient ischemic attack (TIA) or intracranial neoplasm, arteriovenous malformation, or aneurysm.

- Have an International Normalized Ratio (INR) known to be >1.5 within 1 week of study entry.

- Have a known platelet count of <100,000/mm3 within 1 week of study entry.

- Have known anemia (hemoglobin [Hgb] <10 gm/dL) within 1 week of study entry.

- Are receiving or will receive oral anticoagulation or other antiplatelet therapy (other than ASA) that cannot be safely discontinued for the duration of the trial.

- Are receiving daily treatment with non-steroidal anti-inflammatory drugs (NSAIDS) that cannot be discontinued.

- Have a concomitant medical illness that in the opinion of the investigator may interfere with or prevent completion in this study.

- Have known severe hepatic dysfunction (e.g., cirrhosis or portal hypertension).

- Have a history of intolerance or allergy to ASA or approved thienopyridines (ticlopidine or clopidogrel).

Study Design


Intervention

Drug:
Ticagrelor + Aspirin
Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
Clopidogrel + Aspirin
Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).

Locations

Country Name City State
United States Icahn School of Medicine at Mount Sinai New York New York

Sponsors (2)

Lead Sponsor Collaborator
Juan J Badimon AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Thrombus Formation Thrombus formation in Badimon Perfusion Chamber high-shear) (ex vivo model of thrombosis). up to 7 days
Secondary Platelet Reactivity Platelet reactivity by Multiplate Analyzer up to 7 days
Secondary P2Y12 Reaction Unit (PRU) Platelet reactivity by measuring P2Y12 Reaction Unit using Accumetrics VerifyNow up to 7 days
Secondary Platelet Reactivity Index (PRI) Platelet reactivity index by Vasodilator-Stimulated Phosphoprotein phosphorylation (VASP) assay. up to 7 days
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A